We review and summarize the literature on the safety and stability of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion (CSII) in patients with diabetes.
Methods:
Two predefined search strategies were systematically implemented to search Medline and the Cochrane Register of Clinical Trials for publications between 1996 and 2012.
Results:
Twenty studies were included in the review: 13 in vitro studies and 7 clinical studies. In vitro studies investigated the effects of extreme CSII conditions (high temperature and mechanical agitation) on the risk of catheter occlusions and insulin stability factors, such as potency, purity, high molecular weight protein content, pH stability, and preservative content (m-cresol, phenol). Under these conditions, the overall stability of rapid-acting insulin analogs was similar for insulin lispro, insulin aspart, and insulin glulisine, although insulin glulisine showed greater susceptibility to insulin precipitation and catheter occlusions. A limited number of clinical trials were identified; this evidence-based information suggests that the rate of catheter occlusions in patients with type 1 diabetes using CSII treatment may vary depending on the rapid-acting analog used.
Conclusions:
Based on a limited amount of available data, the safety, stability, and performance of the three available rapid-acting insulin analogs available for use with CSII were similar. However, there is limited evidence suggesting that the risk of occlusion may vary with the insulin preparation under certain circumstances.
PickupJ. Insulin pumps. Int J Clin PractSuppl. 2011; 170: 16–9.
2.
SiebenhoferAPlankJBergholdAJeitlerKHorvathKNarathMGfrererRPieberTR. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006; 2: CD003287.
3.
BolliGBDi MarchiRDParkGDPrammingSKoivistoVA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999; 42 (10): 1151–67.
4.
AndersonJHJrBrunelleRLKoivistoVAPfütznerATrautmannMEVignatiLDiMarchiR. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes. 1997; 46 (2): 265–70.
5.
HoogmaRPSchumickiD. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res. 2006; 38 (6): 429–33.
6.
BodeBW. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine. Endocr Pract. 2011; 17 (2): 271–80.
7.
NielsenLFrokjaerSBrangeJUverskyVNFinkAL. Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry. 2001; 40 (28): 8397–409.
8.
Van BonACBodeBWSert-LangeronCDeVriesJHCharpentierG. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: A randomized controlled trial. Diabetes Technol Ther. 2011; 13 (6): 607–14.
9.
PhillipsBDAurandLABedwellMMLevyJR. A novel approach to preventing diabetic ketoacidosis in a patient treated with an insulin pump. Diabetes Care. 2003; 26 (10): 2960–1.
NaikSKerrDBegleyJMortonJ. Influence of local skin temperature and choice of insulin analog on catheter occlusion rates during continuous insulin infusion: An exploratory study. Diabetes Technol Ther. 2012; 14 (11): 1018–22.
12.
LingJHuMHagerupTCampbellRK. Lispro insulin: Adsorption and stability in selected intravenous devices. Diabetes Educ. 1999; 25 (2): 237–45.
13.
JarsMUHvassAWaabenD. Insulin aspart (AspB28 human insulin) derivatives formed in pharmaceutical solutions. Pharm Res. 2002; 19 (5): 621–8.
14.
JorgensenLBennedsenPHoffmannSVKroghRLPinholtCGroenningMHostrupSBukrinskyJT. Adsorption of insulin with varying self-association profiles to a solid Teflon surface—influence on protein structure, fibrillation tendency and thermal stability. Eur J Pharm Sci. 2011; 42 (5): 509–16.
15.
DeFelippisMRBellMAHeyobJAStormsSM. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2006; 8 (3): 358–68.
16.
LougheedWDZinmanBStrackTRJanisLJWeymouthABBernsteinEAKorbasAMFrankBH. Stability of insulin lispro in insulin infusion systems. Diabetes Care. 1997; 20 (7): 1061–5.
17.
SharrowSDGlassLCDobbinsMA. 14-day in vitro chemical stability of insulin lispro in the minimed paradigm pump. Diabetes Technol Ther. 2012; 14 (3): 264–70.
18.
SenstiusJHarboeEWestermannH. In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed 508 insulin pump. Diabetes Technol Ther. 2007; 9 (1): 75–9.
19.
SenstiusJPoulsenCHvassA. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps. Diabetes Technol Ther. 2007; 9 (6): 517–21.
20.
SeneshGBushiDNetaAYodfatO. Compatibility of insulin lispro, aspart, and glulisine with the Solo micropump, a novel miniature insulin pump. J Diabetes Sci Technol. 2010; 4 (1): 104–10.
21.
PoulsenCLangkjaerLWorsøeC. Precipitation of insulin products used for continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2005; 7 (1): 142–50.
22.
PoulsenCLangkjaerLWorsøeC. Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2007; 9 (1): 26–35.
23.
KerrDMortonJWhately-SmithCEverettJBegleyJP. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Technol. 2008; 2 (3): 450–5.
24.
BodeBWStrangeP. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care. 2001; 24 (1): 69–72.
25.
RaskinPHolcombeJHTamborlaneWVMaloneJIStrowigSAhernJALaventF. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. J Diabetes Complications. 2001; 15 (6): 295–300.
26.
RennerRPfütznerATrautmannMHarzerOSauterKLandgrafR. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care. 1999; 22 (5): 784–8.
27.
BodeBWeinsteinRBellDMcGillJNadeauDRaskinPDavidsonJHenryRHuangWCReinhardtRR. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: A randomized study in type 1 diabetes. Diabetes Care. 2002; 25 (3): 439–44.
28.
BartoloPDPellicanoFScaramuzzaASarduCCasettiTBosiEMiselliVBrandoliniSFabbriTMeandriPCannatàF. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. Diabetes Technol Ther. 2008; 10 (6): 495–8.
29.
WeinzimerSATernandCHowardCChangCTBeckerDJLaffelLM; Insulin Aspart Pediatric Pump Study Group. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care. 2008; 31 (2): 210–5.
30.
BodeBWTamborlaneWVDavidsonPC. Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med. 2002; 111 (5): 69–77.
